This is a working overview of melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Fibromyalgia (FM) is a long-term condition characterised by widespread chronic pain. Other symptoms can include fatigue, trouble thinking or remembering, waking up tired (unrefreshed), pain or cramps in the lower abdomen, depression, or headache. The causes of fibromyalgia are unknown, with several pathophysiologies proposed. Fibromyalgia is estimated to affect 2 to 4% of the population. Women are affected at a higher rate than men. Rates appear similar across areas of the world and among varied cultures. Fibromyalgia was first recognised in the 1950s, and defined in 1990, with updated criteria in 2011, 2016, and 2019. The treatment of fibromyalgia is symptomatic and multidisciplinary. Aerobic and strengthening exercise is recommended. Duloxetine, milnacipran, and pregabalin can give short-term pain relief to some people with FM. Symptoms of fibromyalgia persist long-term in most patients. Fibromyalgia is associated with a significant economic and social burden, and it can cause substantial functional impairment among people with the condition. People with fibromyalgia can be subjected to significant stigma and doubt about the legitimacy of their symptoms, including in the healthcare system. FM is associated with relatively high suicide rates.
Notwithstanding, nutrition labels on Australian food products typically recommend the average daily energy intake of 8,800 kJ (2,100 kcal). The minimum food energy intake is also higher in cold environments. Increased mental activity has been linked with moderately increased brain energy consumption.
As early researchers noted, the strychnine molecular structure, with its specific array of rings, stereocenters, and nitrogen functional groups, is a complex synthetic target, and has stimulated interest for that reason and for interest in the structure–activity relationships underlying its pharmacologic activities. An early synthetic chemist targeting strychnine, Robert Burns Woodward, quoted the chemist who determined its structure through chemical decomposition and related physical studies as saying that "for its molecular size it is the most complex organic substance known" (attributed to Sir Robert Robinson). The first total synthesis of strychnine was reported by the research group of R. B. Woodward in 1954, and is considered a classic in this field. The Woodward account published in 1954 was very brief (3 pages), but was followed by a 42-page report in 1963. The molecule has since received continuing wide attention in the years since for the challenges to synthetic organic strategy and tactics presented by its complexity; its synthesis has been targeted and its stereocontrolled preparation independently achieved by more than a dozen research groups since the first success.
== Function == The compressive forces applied to the foot are distributed along five rays, three medial (side of big toe) and two lateral (side of little toe). The lateral rays stretch over the cuboid bone to the heel bone and the medial rays over the three cuneiform bones and the navicular bone to the ankle bone. Because the ankle bone is placed over the heel bone, these rays are adjacent near the toes but overriding near the heel, and together they form the arches of the foot that are optimized to distributed compressive forces across an uneven terrain. In this context the heel thus forms the posterior point of support that together with the balls of the large and little toes bear the brunt of the loads.
== Chemistry == Three chemical syntheses of zolpidem are common. 4-Methylacetophenone is first brominated and that product is treated with 2-amino-5-methylpyridine to give the imidazopyridine. From here the reactions use a variety of reagents to complete the synthesis, either involving thionyl chloride or sodium cyanide. These reagents are challenging to handle and require thorough safety assessments. Though such safety procedures are common in the industry, they make clandestine manufacture difficult. Several major side-products of the sodium cyanide reaction have been characterised and include dimers and mannich products. Alpidem is also an imidazopyridine and is an analogue of zolpidem. Both agents are GABAA receptor positive allosteric modulators. However, whereas zolpidem is used as a hypnotic and sedative, alpidem was used as an anxiolytic.
Sources: en.wikipedia.org
"Chordate". The Encyclopedia of Life. Chordate on GlobalTwitcher.com Chordate node at Tree Of Life Archived 24 February 2007 at the Wayback Machine Chordate node at NCBI Taxonomy Archived 28 April 2021 at the Wayback Machine
== Real-time air monitoring == The first SCIEX product, introduced in 1979, was the TAGA (Trace Atmospheric Gas Analyzer) quadrupole mass spectrometer system, which used atmospheric-pressure chemical ionization (APCI) for direct air analysis. Use of a cryopump vacuum system run by a liquid helium compressor allowed the instrument to be mounted in a large van for mobile operation, and operated while in motion to monitor concentrations of air pollutants. In 1981, the TAGA 6000, the first commercial triple quadrupole mass spectrometer, was introduced also in both lab-based and mobile configurations. Systems were acquired by, among others, government environmental agencies in Ontario and New York State, and the USEPA, and have been used in various applications such as tracking fugitive emission plumes from industrial sites, analysis of gases from contaminated homes in the Love Canal area and for air monitoring in the Gulf area after the BP spill in 2010. In 1979, the TAGA 3000 was used for real-time monitoring of toxic gas plumes of chlorine, styrene and other gases released from the Mississauga train derailment and fire providing timely information for emergency personnel.
== History == The introduction of the baking of processed cereals, including the creation of flour, provided a more reliable source of food. Egyptian sailors carried a flat brittle loaf of millet bread called dhourra cake. A cracker called bucellatum is known from Ancient Rome. King Richard I of England left for the Third Crusade (1189–1192) with "biskit of muslin", which was a mixed grain compound of barley, bean flour, and rye. The more refined captain's biscuit was made with finer flour. Some 5th century BCE physicians, such as Hippocrates, associated most medical problems with digestion. For sustenance and health, eating a biscuit daily was considered good for one's constitution. Because hardtack biscuits were baked hard, they would stay intact for years if kept dry. For long voyages, hardtack was baked four times, rather than the more common two, and prepared six months before sailing. Because it is dry and hard, hardtack, when properly stored and transported, will survive rough handling and temperature extremes. Dry hardtack is dense and virtually inedible; troops issued it usually made it edible by dampening or crushing the biscuits. When James VI and I set sail for Norway in October 1589, his provisions included 15,000 "bisquit baiks". In 1665, Samuel Pepys first regularized naval victualling in the Royal Navy with varied and nutritious rations, to include "one pound daily of good, clean, sweet, sound, well-baked and well-conditioned wheaten biscuit".
=== Death === Sunny remained in a persistent vegetative state until her death from cardiopulmonary arrest on December 6, 2008, at Mary Manning Walsh Nursing Home in New York City. Her memorial service, given by her three children, was held on January 14, 2009, at the Brick Presbyterian Church in New York, which was the same church where the von Bülows married.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.